Effect of Idarucizumab on Dabigatran-Mediated Anticoagulation Among Patients With Uncontrolled Bleeding (Panels A and C) and Those Who Require Emergent Procedures (Panels B and D)

The analyses included 51 patients who had serious bleeding (group A; Panels A and C) and 39 who required urgent surgery or intervention (group B; Panels B and D). Idarucizumab was administered in two infusions. Blood samples were obtained at baseline, after the first infusion, at 10 to 30 minutes after the administration of the second infusion, and at 1, 2, 4, 12, and 24 hours. Data are presented as box-and-whisker plots, in which the top and bottom of the rectangles indicate the 75th and 25th percentiles, respectively; the horizontal lines within the rectangles indicate the 50th percentile; the lines above and below the rectangles indicate the 90th and 10th percentiles, respectively; and the dots above and below the lines indicate the 95th and 5th percentiles, respectively. The dashed lines indicate the upper limit of the normal range for the tests.

From N Engl J Med, Pollack CV Jr et al., Idarucizumab for Dabigatran Reversal. Copyright © (2015) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.